Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Br J Haematol. 2010 Nov;151(3):221-31. doi: 10.1111/j.1365-2141.2010.08326.x. Epub 2010 Aug 31.
Despite recent therapeutic improvements, the clinical course of diffuse large B-cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi-centre study to evaluate the impact of genomic aberrations detected using a high-density genome wide-single nucleotide polymorphism-based array on clinical outcome in a population of DLBCL patients treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R-CHOP-21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p- and 15q-. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R-CHOP, have been identified by arrayCGH.
尽管最近的治疗有所改善，但弥漫性大 B 细胞淋巴瘤（DLBCL）的临床病程在患者之间仍有很大差异。我们进行了这项回顾性多中心研究，以评估使用高密度全基因组单核苷酸多态性芯片检测到的基因组异常对接受 R-CHOP-21（利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松每 21 天重复一次）治疗的 DLBCL 患者临床结局的影响。使用 GeneChip Human Mapping 250K NspI 分析了 166 个 DNA 样本。分析了基因组异常对 124 例接受 R-CHOP-21 治疗的患者临床病程的影响。进行了无监督聚类以确定具有不同临床结局的遗传相关亚组患者。20 个复发性遗传病变对临床病程有影响。8p23.1 处的基因组物质缺失显示出最强的统计学意义，并与 17p-和 15q-等其他异常相关。无监督聚类确定了五个具有不同遗传特征、临床特征和结局的 DLBCL 聚类。通过 arrayCGH 确定了与接受 R-CHOP 治疗的患者不同结局相关的遗传特征和聚类。
